Takeda Pharmaceutical Co. Ltd.’s plan to increase annual revenue to JPY5,000bn ($48bn) by fiscal year 2030 hit a roadblock on 5 October when the company said it stopped two mid-stage clinical trials for its narcolepsy drug candidate TAK-994 due to a safety signal observed in the studies. The oral therapy is part of a portfolio of orexin agonists that Takeda forecast to generate up to $6bn in revenue across narcolepsy types 1 and 2 and idiopathic hypersomnia.
The Japanese big pharma did not outline the type of safety signal it saw in the placebo-controlled Phase II trials...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?